Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
← catalyst calendarNCT06906341 · readout ≤ 11 d
Sponsored by Corcept Therapeutics (industry) · CORT — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
270estimated
Sites
49
Countries
Belgium, France, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-11 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
- Endometrial Cancer
Interventions
- Drug: Relacorilant 150 mg once daily (QD) — also filed as CORT125134
- Drug: Nab-paclitaxel 80 mg/m^2
- Drug: Bevacizumab 10 mg/kg
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS)
measured Date of first dose until PD or death, up to 18 months
Permalink · CORT's whole pipeline · Catalyst calendar · Every registered study · What changed